Description_x000D_ Specificity_x000D_ Inhibits serine, cysteine, aspartic, and metalloproteases._x000D_ Application_x000D_ Optimized and tested for general use._x000D_ SIGMAFAST™ Protease Inhibitor Tablets has been used to collect tracheae in combination with ice-cold radioimmunoprecipitation assay buffer in a study to determine the tracheal basal cell fate. It has been used to homogenize rat lung tissues for western blot analysis._x000D_ Components_x000D_ AEBSF, 2 mM_x000D_ Aprotinin, 0.3 μM_x000D_ Bestatin, 130 μM_x000D_ EDTA, 1 mM_x000D_ E-64, 14 μM_x000D_ Leupeptin, 1 μM_x000D_ Other Notes_x000D_ Tableted formulation containing water-soluble protease inhibitors with broad specificity for the inhibition of serine, cysteine, and metalloproteases. Contains 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), E-64, bestatin, leupeptin, aprotinin, and EDTA (sodium salt)._x000D_ Quantity_x000D_ One tablet makes 100 mL of cocktail. One mL is recommended for the inhibition of proteases equivalent to 1 mg of USP pancreatin. One tablet is recommended for the inhibition of proteases present in a maximum of 20 g of cell extract._x000D_ Physical form_x000D_ Tablet that is water soluble._x000D_ Legal Information_x000D_ SIGMAFAST is a trademark of Sigma-Aldrich Co. LLC